Lyell Immunopharma (LYEL) IPO Opens 10% Higher

Today's IPO for Lyell Immunopharma, Inc., (Nasdaq: LYEL) opened for trading at $18.75 after pricing 25,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Lyell.

Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering.

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• RMG Acquisition Corp. III (RMGCU) Cancels Dissolution
• Centuri (CTRI) Opens At $23.75, IPO At $21 (earlier)